OKYO Pharma Ltd (OKYO): Forward Price-to-Revenue Multiple

Corporate emblem and logo of OKYO Pharma Limited (OKYO)

The success of OKYO Pharma Limited (OKYO) is contingent upon the test results of OK-101 for ocular inflammation. The forward EV/Revenue multiple reflects the valuation trend, with the current value standing at . While a single-product strategy introduces risks, it targets a broad consumer segment. The biopharma business in the US and UK relies on a narrow treatment profile for mucosal dryness.

OKYO OKYO Pharma Inc: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/16/2026

Financial and market metric breakdowns for OKYO Pharma (OKYO)

- market price and analyst price targets:
- stock exchange capitalization data:
Summary company analysis:OKYO Pharma Limited OKYO
Original product of okyopharma.com

OKYO Pharma Limited (OKYO) strategic alliances in ophthalmology are driving capitalization dynamics, as clearly reflected in the forward P/S history. This indicator benchmarks the company's market value against expected revenue, allowing investors to assess whether the premium for innovation scalability is justified and to identify the risk of overpaying during peaks of optimism, thereby confirming the fundamental stability of the capital.